Company: Confidential large hospital and healthcare-services group
Board location: Chennai, with hospital reviews across South and East India
Appointment: Independent Director, Non-Executive
Intended committee role: Chair, Clinical Governance, Ethics & Patient Safety Committee; member, Audit and Risk Committees
Expected commitment: 30–38 days annually, including Board and committee preparation, unannounced clinical-governance visits, mortality and sentinel-event reviews, and an annual strategy session
Company context
The group operates a multi-city network of tertiary and quaternary hospitals with approximately 3,500–5,000 operational beds. Its principal specialties include cardiac sciences, oncology, neurosciences, renal care, transplant, orthopaedics, critical care and complex surgery. Growth is being pursued through brownfield bed additions, selective acquisitions, day-care formats, international-patient channels and digital care coordination.
Revenue is drawn from self-pay patients, insurers and third-party administrators, government schemes, corporate contracts and international patients. Clinical talent, high-cost equipment, pharmacy and implant procurement, bed utilisation and payor authorisation all influence margin. The same variables also affect clinical appropriateness, access, patient experience and trust.
Board mandate
The Independent Director will make clinical quality, patient safety, medical ethics and payor integrity visible as enterprise risks and sources of durable value. The role will challenge the Board to judge performance through risk-adjusted outcomes, patient experience, clinical appropriateness and cash quality—not occupancy, average revenue per occupied bed or procedure growth alone.
The appointee will not determine individual treatment, act as an appellate clinician, intervene in doctor employment disputes or direct hospital operations. The committee will set governance standards, investigate systemic risk, protect speaking-up and hold management accountable for verified improvement.
Strategic agenda
-
Clinical outcome architecture: Establish specialty-level outcome measures adjusted for case severity, including mortality, complications, readmission, infection, re-intervention, length of stay and functional recovery. Prevent comparisons that reward avoidance of complex patients or penalise centres taking appropriate high-risk cases.
-
Mortality, morbidity and sentinel events: Require timely, protected and multidisciplinary review of unexpected deaths, wrong-site or wrong-patient events, retained objects, transfusion errors, medication harm, falls, maternal events, device failures and delayed escalation. Track recurring system causes and closure effectiveness rather than event counts alone.
-
Credentialing and clinical privileges: Govern initial appointment, specialty privileges, proctoring, renewal, complication thresholds and suspension for consultants and employed doctors. Revenue contribution, reputation or referral power must never override evidence of competence, behaviour or patient safety.
-
Clinical appropriateness and utilisation: Use peer review and data to examine avoidable admissions, diagnostics, ICU use, implants, procedures and length of stay. Distinguish warranted clinical variation from incentive-driven overuse, defensive medicine or under-treatment created by package economics.
-
Doctor engagement and incentives: Review fee sharing, minimum guarantees, revenue shares, referral arrangements, exclusivity, retention payments and productivity measures. Incentives must not reward unnecessary intervention, self-referral, brand-specific implant selection or delayed discharge.
-
Patient consent and ethics: Strengthen informed consent for complex surgery, transplant, oncology, experimental or high-cost treatment and use of patient data. Consent must communicate alternatives, material risks, financial implications and likely outcomes in language the patient can understand.
-
Payor and billing integrity: Reconcile clinical documentation, coding, package terms, pre-authorisation, exclusions, consumables, implants, denials and collections. Identify systematic upcoding, unbundling, undocumented care, avoidable denials and pressure to alter clinical records after treatment.
-
Government-scheme governance: Monitor eligibility, package compliance, patient selection, claim rejection, delayed payment and service quality. Commercial pressure must not produce discrimination between scheme, insured and self-pay patients where clinical need is comparable.
-
Pharmacy, implants and procurement: Govern formularies, antibiotic stewardship, implant choice, rebates, vendor sponsorship, consignment, expiry, substitution and conflict disclosure. Clinical leaders involved in product selection must declare financial or professional relationships.
-
Infection prevention and antimicrobial resistance: Set network standards for surveillance, hand hygiene, isolation, sterile processing, environmental cleaning, device-associated infections and antimicrobial use. Require independent validation where unit results appear implausibly favourable.
-
Capacity and capital allocation: Assess new beds, operating theatres, robots, radiation equipment, transplant programmes and acquisitions through catchment, clinician availability, referral depth, licence readiness, ramp losses, clinical volume thresholds and return on invested capital.
-
Hospital acquisition integration: Require pre-acquisition diligence on licences, medical records, physician contracts, quality events, claims, infection, equipment, fire and life safety, biomedical waste and culture. Integration milestones must include clinical systems and patient safety, not finance and branding alone.
-
Workforce resilience: Review nurse-to-patient ratios, critical-care competence, resident coverage, technician certification, fatigue, attrition, workplace violence, psychological safety and succession for clinical leaders. Agency staffing must be governed to the same competency standard as permanent staff.
-
Digital health and patient data: Govern electronic medical records, clinical decision support, telemedicine, connected devices and AI tools for diagnosis, triage, coding and documentation. Require validation, human accountability, access controls, downtime procedures and protection of sensitive health data.
-
Emergency and infrastructure resilience: Test oxygen, power, fire, medical-gas, HVAC, water, blood, critical supplies, cyber downtime and mass-casualty readiness. Closure must be based on live simulations and independently observed recovery, not checklist completion.
Matters requiring direct Board judgement
- Suspension or restriction of a high-revenue clinician following an adverse outcome pattern or behavioural concern.
- Expansion of a complex specialty into a hospital that has attractive demand but inadequate clinical depth or emergency support.
- Continuation of an insurer or government contract whose package economics encourage compromised care or repeated documentation disputes.
- Acquisition of a profitable hospital with weak incident reporting, concentrated doctor relationships or unresolved licence exposure.
- Public disclosure and patient remediation after a systemic clinical, cyber or billing failure.
- Approval of high-cost technology whose marketing value is clear but clinical utilisation and outcome advantage are uncertain.
Candidate profile
Essential experience
- Former hospital-network CEO, chief medical or clinical officer, healthcare regulator, senior clinician with enterprise governance experience, health-insurance leader or healthcare operating executive.
- Direct accountability for clinical quality, patient safety, hospital operations, medical ethics or healthcare payment integrity at meaningful scale.
- Experience handling a serious clinical event, quality remediation, hospital integration or payor dispute with transparent governance.
- Ability to read clinical and financial evidence together and to challenge eminent physicians, executives and investors respectfully but firmly.
- Strong understanding of Board confidentiality, committee authority and the boundary between governance and individual clinical decisions.
Preferred experience
- Quaternary specialties, multi-hospital networks, accreditation or international patient care.
- Audit Committee experience involving revenue recognition, claims, provisions, doctor arrangements or acquisitions.
- Healthcare technology, clinical AI, data privacy or cyber resilience.
- Workforce, nursing-quality or clinical-leadership succession governance.
Independence and eligibility
- Active inclusion in the IICA Independent Directors Databank, with the applicable proficiency-test requirement completed or a valid exemption documented.
- Satisfaction of statutory independence, DIN, KYC, disqualification, directorship and committee-capacity conditions.
- No material relationship with significant shareholders, competing hospital chains, major payors, pharmaceutical or implant suppliers, laboratories, equipment vendors, statutory auditors, acquisition targets or professional advisers to the group.
- Disclosure of medical practice, referral relationships, research support, speaking fees, clinical trials, hospital privileges, insurer panels, charitable trusteeships, investments and close-relative employment.
First-year Board outcomes
- A trusted network-wide clinical outcome and sentinel-event dashboard with severity adjustment and independent validation.
- Credentialing and clinical-privilege decisions insulated from revenue and referral influence.
- Board-approved controls for billing, coding, payor denials, doctor incentives and high-risk procurement.
- Evidence-based capital gates for new beds, specialties, equipment and hospital acquisitions.
- Tested emergency, cyber-downtime and patient-data response with material gaps assigned and closed.